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The physiological hydroelectrolytic balance and the redox steady state in the kidney are accomplished by an intricate interaction
between signals from extrarenal and intrarenal sources and between antinatriuretic and natriuretic factors. Angiotensin II, atrial
natriuretic peptide and intrarenal dopamine play a pivotal role in this interactive network. The balance between endogenous
antioxidant agents like the renal dopaminergic system and atrial natriuretic peptide, by one side, and the prooxidant effect of the
renin angiotensin system, by the other side, contributes to ensuring the normal function of the kidney. Different pathological
scenarios, as nephrotic syndrome and hypertension, where renal sodium excretion is altered, are associated with an impaired
interaction between two natriuretic systems as the renal dopaminergic system and atrial natriuretic peptide that may be involved
in the pathogenesis of renal diseases. The aim of this review is to update and comment the most recent evidences about the
intracellular pathways involved in the relationship between endogenous antioxidant agents like the renal dopaminergic system
and atrial natriuretic peptide and the prooxidant effect of the renin angiotensin system in the pathogenesis of renal inflammation.
1. Introduction
A normal redox state of cells depends on a delicate balance
between oxidative species and antioxidant mechanisms. Act-
ing as cellular messengers, reactive oxygen species (ROS)
are involved in the destruction of invading pathogens [1].
Chronic inflammatory conditions such as atherosclerosis or
hypertension can alter the normal redox state of the cells
through an overproduction of free radicals that leads to an
increase in oxidative stress with disruption of the normal
cellular signaling mechanisms [2–5]. In the kidney, oxidative
stress and infiltration of inflammatory cells represent key
factors for the development of renal injury and hypertension
[6]. Angiotensin II (Ang II) that displays hypertensive and
prooxidant properties, by one side, and the atrial natriuretic
peptide (ANP) and renal dopamine, by the other side,
both with hypotensive and antioxidant properties, are local
factors closely related to the development and progression of
glomerular and tubular injury [7, 8].
2. Renin-Angiotensin System
and Renal Oxidative Stress
Ang II mediates most of the renin angiotensin system (RAS)
effects through activation of two types of receptors: Ang II
type 1 (AT1R) and Ang II type 2 (AT2R). In the last decades,
novel components of the RAS have been recognized, includ-
ing the (pro) renin receptor, the angiotensin-converting
enzyme type 2 (ACE-2)/Ang (1–7)/Mas axis, and other Ang
peptides (Ang III, IV, 1–5) (Figure 1) [9]. The observation
that angiotensinogen, renin, ACE, and AT1R are expressed in
multiple tissues suggests the existence of multiple local RAS,
acting as independent entities from the systemic RAS [10].
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Figure 1: Metabolism and major functions of angiotensin peptides. Angiotensin-(1–7) is metabolized by angiotensin-converting enzyme
(ACE) to form Ang-(1–5). Angiotensin II (Ang II) is catabolized by aminopeptidase A (APA) to form angiotensin III, which is further
hydrolyzed by aminopeptidase N (APN) to form angiotensin IV. Also, Ang II can be directly cleaved by dipeptidyl aminopeptidase IV (DAP)
to produce Ang IV. Ang-(1–7) binds to Mas receptor to exert anti-inflammatory effects. With author’s permission (S. L. Della Penna).
In particular, there is a local renal RAS that synthesizes and
secretes Ang II, reaching a concentration 100-fold higher in
the lumen than in the plasma [11–13].
The finding that intrarenal Ang II content is elevated
in many forms of hypertension supports the idea that the
intrarenal RAS plays a crucial role in the development of
hypertension and the RAS-associated injury [14]. Further-
more, renal RAS overactivity is associated with the develop-
ment of diverse pathological processes in the kidney, includ-
ing glomerular sclerosis, diabetic nephropathy, and renal
artery stenosis [15, 16]. Indeed, experiments in gene-targeted
mice demonstrated that the elevation of the locally produced
renal Ang II induced the elevation of blood pressure, together
with the development of renal inflammation and fibrosis
[11, 17]. In this way, the use of ACE inhibitors and AT1R
blockers is recommended as first-line therapy in hypertensive
patients with renal disease (Figure 1) [10]. These pharmaco-
logical agents attenuate renal disease in both preclinical and
clinical studies and are effective and well tolerated, and in
addition they improve morbidity and mortality associated
with cardiovascular events [18, 19].Therefore, in pathological
conditions,Ang IImay contribute to impairing renal function
by inducing oxidative stress, inflammation, and fibrosis and
downregulation of water channels aquaporins [12, 20–26]. It
must be pointed out that these processes could be detected
before the elevation of blood pressure and even when the
systemic RAS was inhibited [11, 26].
Besides the systemic and the local tissue RAS, the pres-
ence of an intracrine or intracellular RAS has been recently
described [27]. Synthesized Ang II within the cell binds to
intracellular and/or nuclear AT1R, AT2R, or Mas receptors
and activates downstream signalling pathways. By this way,
intracellular Ang II can induce cellular or nuclear responses
independently of its cell surface receptors [27–30].These and
other findings provided new knowledge about novel roles of
the RAS in many fields, beyond blood pressure control.
In the kidney, AT1R mediates vasoconstriction of glom-
erular microvasculature, modifying the glomerular filtration
rate, the tubuloglomerular feedback, and cell growth [10].
Moreover, Ang II modifies, through this receptor, the activity
of different transporters in the kidney such as Na+/H+
exchanger (NHE), epithelial sodium channels (ENaCs), Na-
K-2Cl cotransporter (NKCC2), and Na-Cl cotransporter
(NCC) [10, 31]. Overall, these actions contribute to an
increased capacity of the kidney to preserve sodium and
maintain blood pressure within normal values. The AT2R
is localized in glomerular epithelial cells, proximal tubules,
collecting ducts, and renal vasculature. It is considered as a
functional antagonist ofAT1R and is associatedwith vasodila-
tion, apoptosis, antiproliferation, and increase of natriuresis,
by stimulation of nitric oxide/cGMP/protein-kinase G (PKG)
pathway [32]. Activation of AT2R induces stimulation of
endothelial nitric oxide synthase (eNOS) to produce nitric
oxide (NO) that is a potent vasodilatormolecule and essential
for the maintenance of cardiovascular health [33].
The AT1R is a member of the G protein-coupled receptor
family associated with Gq/11, Gi, G
12
, and/or G
13
[34]. Ang
II binding to AT1R leads to activation of phospholipase
C (PLC), A2 (PLA
2
), or D (PLD), which ultimately raise
intracellular second messengers inositol-1,4,5-triphosphate
(IP
3
), diacylglycerol, arachidonic acid, Ca2+, and ROS con-
centrations [35].These signaling factors subsequently activate
Rho kinase and mitogen-activated protein kinases (MAPK)
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including p44/42 MAPK, p38 MAPK, and c-jun N-terminal
kinase [36, 37]. However, G protein independent pathways
can also play a crucial role on the development of patho-
physiological processes. In this way, it has been recently
demonstrated that Janus kinase (JAK) is elicited byAng II as a
key target in the development of RAS-associated diseases like
hypertension [38]. On the other hand, the RAS and inflam-
matory cytokines can synergize their effects to elevate blood
pressure [13]. Circulating Ang II, as well as locally produced
Ang II, can increase cytokine levels, including interleukin 6
(IL-6) and interferon 𝛾 (IFN-𝛾), which in turn synergize the
activation of Janus kinase/signal transducers and activators of
transcription (JAK/STAT) pathway. This cascade of events is
finally a potent stimulus for angiotensinogen expression and
thereby contributes to increase the local synthesis of Ang II
and the progression of hypertension and the establishment of
renal injury.
ROS play an important pathophysiological role in the
kidney [33, 39–41]. Nicotinamide adenine dinucleotide phos-
phate reduced form (NADPH) oxidase is a predominant
enzyme involved in the development of oxidative stress; it is
upregulated by the increase of sodium tubular transport, or
luminal flow, or by cytokines release [42, 43]. ROSproduction
activates several intracellular signalling mechanisms, such
as AP-1 (activator protein-1) and NF-𝜅B (nuclear factor-𝜅B)
transcription factors [44, 45]. When Ang II binds to AT1R,
it stimulates NADPH oxidase, magnifying the production of
ROS, such as superoxide anion (O
2
−). In turn, the superoxide
anion increases tubular NaCl transport, enhancing further
the oxidative stress. ROS can also activate the mitochondrial
uncoupling protein 2 (UCP-2), leading to an inefficient use of
renal O
2
and contributing to renal hypoxia [46]. Changes in
cellular oxygen concentrations induce the response of tightly
regulated pathways that attempt to restore oxygen supply to
cells and modulate the cell function under hypoxic condi-
tions. Most of these responses are mediated by the induction
of the transcription factor hypoxia-inducible factor-1𝛼 (HIF-
1𝛼) which coordinates the expression of diverse adaptive
genes against the hypoxic injury [47, 48]. HIF-1𝛼 is stabilized
by the sum of opposed effects: by one hand, the increase of
sodium transport by the tubules generates relative hypoxia
into the cells, thereby increasing HIF-1𝛼; but on the other
hand, HIF-1𝛼 can be diminished by the oxidative stress,
induced by the increase in sodium transport. Even though the
oxidative stress diminishes the efficiency of the use of oxygen,
thereby increasing hypoxia, it also increases the proteasomal
degradation of HIF-1𝛼, contributing to its catabolism and
diminishing its concentration. HIF-1𝛼 upregulates the tran-
scription of metabolic proteins (GLUT-1), adhesion proteins
(integrins), soluble growth factors (TGF-𝛽 and VEGF), and
extracellular matrix components (as type I collagen and
fibronectin), which enhance the repair process. For these
reasons, HIF-1𝛼 is considered as a positive regulator of
organ repair and tissue fibrosis [49, 50]. It is known that
transforming growth factor-beta1 (TGF-𝛽1) upregulates the
transcription of the serum and glucocorticoid-dependent
kinase hSGK1, involved in the regulation of two important
factors for cell volume regulation, as the renal epithelial
Na+ channel ENaC and the thick ascending limb Na+, K+,
2Cl− cotransporter NKCC [51]. The increase of cell volume
stimulates protein synthesis and inhibits protein degradation,
contributing to enhancing the net formation and deposi-
tion of matrix proteins. In addition, TGF-𝛽1 transduces
intracellular signals through type 1 (TGF-𝛽R1) and type 2
(TGF-𝛽R2) receptors, via the nuclear translocation of Smad3
proteins, thus contributing to a fibrotic response [52]. Recent
studies show that TGF-𝛽1 stimulates angiotensinogen gene
expression and its action through ROS generation, p38
MAPK activation, and p53 expression [53]. Ang II directly
stimulates nuclear AT(1a) receptors and markedly increases
in vitro transcription of mRNAs for TGF-𝛽1 [54]. These
mechanisms suggest that Ang II and TGF-𝛽1 may form
a positive feedback loop to enhance their respective gene
expression leading to renal injury. Ang II also induces NF-
𝜅B subunit p65 phosphorylation and its nuclear translocation
[55]. NF-𝜅B activates genes involved in the inflammatory and
fibrotic responses, which are characterized by infiltration of
monocytes/macrophages and lymphocytes and upregulation
of Ang II and other proinflammatory factors such as adhesion
molecules (V-CAM 1 and I-CAM 1), chemokines (MCP-1 and
RANTES), and cytokines (TGF-𝛽1) [9, 56–58]. Furthermore,
gene silencing of ILK (integrin-linked kinase) prevented
the upregulation of NF-𝜅B-related proinflammatory gene,
demonstrating that ILK plays a pivotal role in the mod-
ulation of inflammation by regulating the NF-𝜅B pathway
and suggests a potential therapeutic target to be used in the
inflammatory renal disease produced by Ang II. In addition,
intrarenal Ang II production is highly stimulated by the
excess of salt in the diet [10, 21, 59]. A renal proinflamma-
tory response, secondary to the excess of sodium, favours
further sodium retention and thus the development of arterial
hypertension [21, 60, 61]. The molecular mechanisms of the
inflammatory response to salt-sensitive hypertension remain
to be completely characterized. The increase in sodium reab-
sorption in the renal tubules leads to elevated blood flow and
thus to glomerular hyperfiltration.This process augments the
metabolic demand of oxygen, which results in a decrease in
tissue oxygen tension [62]. The rise in oxygen consumption
leads to relative hypoxia that triggers a cascade of events,
magnifying ROS production and stimulating the expression
of local Ang II and proinflammatory genes (Figure 2).
A growing number of mammalian genes, including ANP,
have been identified to play a key role in the cellular adaptive
response to counterregulate renal hypoxia and development
of fibrosis. In this way, ANP exerts protective effects in several
types of cells in response to oxidative stress, fibrosis, and
adaptation to hypoxia [63–65].
3. Oxidative Stress and Nephroprotective
Actions of Atrial Natriuretic Peptide
ANP is a member of the natriuretic peptide family and is
synthesized and stored in the atrial myocytes and released
in response to the cardiac wall stretching or after endothe-
lin, cytokine, or 𝛼-adrenergic stimulation [66–68]. ANP
can regulate blood pressure and volume homeostasis by
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Figure 2: Interaction between renin angiotensin system and oxidative stress. (1) ROS can activate the mitochondrial uncoupling protein
2 (UCP-2), leading to inefficient renal O
2
usage and contributing to renal hypoxia. (2) Hypoxia induces the transcription factor
hypoxia-inducible factor-1𝛼 (HIF-1𝛼) which coordinates the expression of diverse adaptive genes against the hypoxic injury. (3) HIF-1𝛼
transcriptionally upregulates the expression of soluble growth factors (TGF-𝛽 and VEGF). (4) Increased sodium tubular transport, luminal
flow, or cytokines release upregulates NADPH oxidase, which produces ROS. (5) Superoxide anion increases Na-K-2Cl cotransport activity
in the thick ascending limb, enhancing further oxidative stress. (6) Hypoxia regulates ANP. (7) ANP in addition to its natriuretic actions
exerts protective effects on several cell types in response to the oxidative stress and fibrosis and on the adaptation to hypoxia. (8) TGF-𝛽1
upregulates the transcription of serum and glucocorticoid-dependent kinase hSGK1, involved in the regulation of two important factors
for cell volume regulation, as the renal epithelial Na+ channel ENaC and the thick ascending limb Na+, K+, 2Cl− cotransporter NKCC. (9)
ROS, especially superoxide, degradeHIF-1𝛼 by activating ubiquitin-proteasome and thereby decrease the activation ofmany oxygen-sensitive
genes. (10) Angiotensin-converting enzyme 2 regulates renal ANP through angiotensin-(1–7). (11) The signal transduction of Ang II through
AT1R enhances ROS production. (12) NADPH oxidase contributes to renal damage through NF-𝜅B.
its natriuretic, diuretic, vasodilator, and renin-angiotensin-
aldosterone suppressor activities [69]. It has been demon-
strated that ANP can also act as an autocrine/paracrine factor
in several organs, such as kidney, lung, thymus, and liver
[70–73]. In fact, many studies have proposed the kidney
as a source of ANP [74, 75]. All these findings together
suggest new biological actions of ANP besides its classical
natriuretic, diuretic, and vasodilator effects. ANP exerts these
actions by its binding to specific receptors. There are three
classes of natriuretic peptide receptors identified (NPRA,
NPRB, and NPRC) usually located on the plasma membrane
of target cells [76, 77]. In the kidney, mRNA and protein
expression of both NPRA and NPRC receptors have been
demonstrated [78–80]. ANP exerts itsmain biological actions
by binding to NPRA, which has intrinsic guanylate cyclase
(GC) activity. Besides the GC domain, it also contains
an extracellular binding domain (ECD) and a preserved
intracellular kinase homology domain (KHD). Activation
of the intrinsic GC domain by ANP binding to the ECD
increases intracellular guanosine 3,5-cyclic monophosphate
(cGMP) levels, which has three known cGMP binding
proteins: cGMP-dependent protein kinases (PKG), cGMP-
binding phosphodiesterases (PDEs), and cyclic nucleotide-
gated (CNG) ion channels [81].The activation of PKG triggers
different events related to cell growth, apoptosis, prolifera-
tion, and inflammation [82]. PDEs degrade cyclic nucleotides
into inactive 5󸀠-nucleotide monophosphates, being crucial
regulators of cyclic nucleotide signalling [81]. NPRC exists
as a homodimer linked by disulfide bonds and has a single
transmembrane domain, an ECD homologous to NPRA, and
a short cytoplasmic domain [83]. NPRC was first considered
as a clearance receptor without any physiological actions,
playing its role during internalization and removal of the
hormone from the circulation [84]. However, it has been
proved that NPRC can elicit physiological functions by its
coupling to adenylyl cyclase (AC) inhibition through an
inhibitory guanine nucleotide-regulatory protein (Gi) and/or
by activation of PLC [85]. The model of NPRC gene (Npr3)
knockout mice showed that both homozygotes and heterozy-
gotes mice have altered cardiovascular and renal functions,
with reduced ability to concentrate urine,mild diuresis, blood
volume depleted, and blood pressure values below normal
levels. These changes suggest that NPRC would modulate
the local availability of natriuretic peptides, allowing them
to response to specific local needs. Moreover, homozygotes
had skeletal deformities, pointing out the importance of these
peptides in the process of bone formation [86].
Besides its role in the regulation of blood pressure and
volume homeostasis, it has been reported that ANP can exert
protective effects in response to oxidative stress, fibrosis,
and the adaptation to hypoxia [63–65]. However, little is
known about the role exerted by ANP in the kidney in
such states. In this sense, Koga et al. showed that ANP has
antioxidant effects in rats, as demonstrated by its ability
to attenuate ROS levels in a renal ischemia-reperfusion
injury model [87]. In another study, Finch et al. showed
that, in uremic rats, the progression of renal worsening and
oxidative stress was accompanied by the increase in 133-fold
of ANPmRNA in tandem together with an increase in blood
pressure, suggesting that ANP mRNA increase would act
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Figure 3: Effects of ANP onNOS activity in the kidney. NO synthesis can be stimulated byANP via NPRA receptors. It has also been reported
thatNPRCnatriuretic receptormediates the activation ofNOSbyANP.This evidence is in accordancewith studies supporting a protective role
of ANP against oxidative stress. In contrast, there is evidence indicating that ANP inhibits the inducible nitric oxide synthase (iNOS) activity
via NPRC, leading to the increase of NO levels. It has been shown that an increment in renal NOS activity together with ROS production
(represented as superoxide anion O
2
−) is able to increase cytotoxic peroxynitrites (ONOO−) which in turn reduce NO bioavailability, leading
to oxidative stress.Themechanisms bywhichANP regulatesNOS activity in the kidney are not completely elucidated (blue arrow: stimulatory
effect, red arrow: inhibitory effect, questionmark: contradictory evidence supporting both stimulatory and inhibitory effects of ANP onNOS
activity, and PDE: phosphodiesterase).
as a protective mechanism [88]. Several experimental data
show that hypoxia is an independent factor that regulates
the synthesis and release of natriuretic peptides. It has been
reported by Chun et al. that, in cultured atrial myocytes
without any stretch changes, hypoxia stimulated the ANP
gene expression, enabling the localization and characteriza-
tion of a 120 bp region of hypoxia-response elements within
the ANP gene promoter [89]. In this sense, Della Penna et al.
demonstrated a significant increase in HIF-1𝛼 expression
associatedwith augmenting intrarenalANP levels, suggesting
a potential adaptive mechanism by which intrarenal ANP
levels would rise in response to the oxidative stress produced
in the kidney of rats chronically fed with a high sodium diet
[90].
On the other hand, it has been shown that an increment
in renal NOS activity together with ROS production is able
to increase cytotoxic peroxynitrites which in turn reduce
NO bioavailability, leading to oxidative stress [91]. There are
contradictory evidences regarding the effects of ANP on the
activity of the different renal isoforms of NOS (Figure 3).
Supporting an antioxidant effect of ANP, McLay et al. have
shown that, in cultures of proximal tubular cells, ANP inhibits
the inducible nitric oxide synthase (iNOS) activity, via NPRC
and cGMP [92]. In addition, Chatterjee et al. showed that,
in human proximal tubular cells, ANP inhibited cytokine-
induced NO synthesis through a cGMP-independent path-
way, involving the NPRC subtype receptor [93]. However,
there is also evidence against the described beneficial effects
of ANP on oxidative stress. In this way, studies performed
in primary cultures of human proximal tubular cells showed
that NO synthesis can be stimulated by ANP via NPRA
receptors [94]. In addition, it has been reported that the
NPRC mediates the activation of NOS by ANP in the kidney
(Figure 3) [95, 96]. Regarding this contradictory evidence, de
Vito et al. suggested that, in different cell types and systems,
ANP could have either antioxidant or prooxidant effects,
depending on the experimental conditions and cell context
[97]. Like the kidney, the cardiovascular system is another
case of conflicting findings. It has been demonstrated in rat
aortic smooth muscle cells that physiological concentrations
of ANP (10−10 to 10−9M) stimulate NPRC and counteract
ROS generation by interfering with the lysophosphatidic
acid dependent phosphoinositide 3-kinase/ROS/MAPK acti-
vation [98]. Moreover, in vascular smooth muscle cells from
hypertensive rats, the activation of NPRC by the ring-
deleted analog C-ANP4-23 decreased the enhanced expres-
sion of Nox4 and p47-phox subunits of NADPH oxidase,
removing the enhanced oxidative stress and acting as a
potent antioxidant [99]. In contrast, in human umbilical
vein endothelial cells, ANP is able to induce mitogen-
activated protein kinase phosphatase-1 via the Rac-1 subunit
of NADPH oxidase and superoxide generation, suggesting a
prooxidant role of ANP [100]. Furthermore, a study carried
out in human macrophages showed that ANP was able to
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induce ROS generation by inhibition of sodium/hydrogen
exchanger (NHE) activity and by increasing PLD activity
with subsequent activation of NADPH oxidase [101]. Finally,
in human endothelial cells, ANP induced the activation of
MAPK phosphatase-1 via Rac1 and NADPH oxidase/Nox2
activation [100]. There is no data about the role of ANP
on NADPH oxidase activity in the kidney. Therefore, fur-
ther investigation is needed to complete the understanding
of ANP role as nephroprotective agent against oxidative
stress.
As a physiological antagonist, ANP may counterregulate
RAS activity not only through its natriuretic and vasodilatory
properties, but also at different stages of the inflammatory
and fibrotic processes [102, 103]. Interestingly, ANP has been
shown to regulate eNOS and iNOS activities in blood vessel
endothelium, by means of two different pathways: via ame-
lioration of endothelium dependent NO synthesis and also
by the concomitant inhibition of cytokine mediated iNOS
expression.Moreover, it has been described that ANP inhibits
nuclear factor NF-𝜅B activation and inflammatory mediators
like iNOS, cyclooxygenase-2, and TNF-𝛼, thus decreasing
peroxynitrites, cytokines, and chemokines production [73,
104–108]. The increase of mRNA expression of TNF-𝛼, IL-
1𝛽, and IL-6 in the kidney and in the lung was reported
in a rat model of renal ischemia-reperfusion injury, with
that increment being abolished by pretreatment with ANP
[109]. Moreover, Lo et al. demonstrated that endogenous
ANP exhibited auto/paracrine effects in renal tubular cells,
counteracting the hyperglycemia stimulated by TGF-𝛽1 and
NF-𝜅B overexpression [110]. ANP also induces the expression
of the NF-𝜅B inhibitor I𝜅B, whose transcriptional induction
is suggested to be a key step in the inhibitory action
of ANP on NF-𝜅B activation [104]. On the other hand,
Das et al. demonstrated that renal NF-𝜅B activity increased
in the model of NPRA gene knockout mice, stimulating
the synthesis of proinflammatory cytokines to produce renal
abnormalities. This suggests that NPRA could contribute to
counterregulating the effects of NF-𝜅B signaling pathway in
the kidney, thus providing renoprotection [111]. All these
findings suggest the anti-inflammatory role of ANP, inde-
pendently of its hemodynamic actions. Likewise, in human
proximal tubular cells, ANP inhibits cytokine-induced NO
synthesis through a cGMP-independent pathway, involving
the NPRC subtype receptor [112]; meanwhile in micro-
and macrovascular endothelial cells, ANP inhibits hypoxia-
induced inflammatory pathways [73, 112]. Furthermore, it has
been demonstrated that the activation of ANP/cGMP/PKG
signaling favors the phosphorylation of Smad3 and disrupts
TGF-𝛽1-induced nuclear translocation of pSmad3 and also,
later downstream events, including myofibroblast transfor-
mation and the proliferation and expression of extracellular
matrix molecules [113]. Roso´n et al. [21] have described that
a hypertonic sodium overload in normal rats generates a cas-
cade of events in the kidney, including higher sodium tubular
reabsorption, which is able to increase oxygen demand,
accompanied by an increase in local Ang II, nuclear factor
NF-𝜅B activation and TGF-𝛽1 expression. In this regard, this
early inflammatory response was prevented and reversed by
the administration of low and nonhypotensive doses of ANP.
This was associated with downregulation of NF-𝜅B and local
Ang II, as well as diminished hypoxia evaluated through
upregulation of HIF-1𝛼 expression. Taken together, these
results suggest a possible mechanism by which ANP could be
acting directly on the inflammatory response inhibiting NF-
𝜅B and Ang II and consequently in an indirect way on the
inhibition of ROS production, thereby protecting cells from
hypoxia and inflammation [21].
4. Antioxidant Properties of the Renal
Dopaminergic System
The renal dopaminergic system is a local independent natri-
uretic system necessary to maintain the normal balance of
sodium and water, blood pressure levels, and renal redox
steady state.Different findings fromexperimental and clinical
studies highlight the participation of renal dopamine in
the pathophysiology of renal inflammation, hypertension,
diabetic nephropathy, and edema [114–117]. The relationship
between dopamine receptors and oxidative stress was not
established until the past decade. Although it still remains
a subject of intense debate and continuous investigation,
different evidences provide a better understanding about the
mechanism by which oxidative species and renal dopamine
interact at renal tubular level.
Renal locally formed dopamine is a major regulator of
proximal tubule salt and water reabsorption and exerts its
physiological actions through two different receptors located
at the tubular cell surface: D1 receptor subtype (D1R, a
member of the D1-like receptor family together with D5R)
and D2 receptor subtype (D2R, a member of the D2-like
receptor as well as D3R and D4R) [118–121]. By activation
of these receptors, dopamine increases renal blood flow
and elicits a marked natriuretic response [120–122]. The
importance of dopamine as a natriuretic hormone is reflected
by its capacity to inhibit sodium transporters almost in the
entire nephron [123]. The D1-like receptors, coupled to the
stimulatory G proteins G𝛼
𝑠
and Golf , are characterized by
their capacity to activateAC,whileD2-like receptors, coupled
to the inhibitory G proteins G𝛼
𝑖
and G
𝑜
, are characterized
by their capacity to inhibit AC and modulate ion channels
[124, 125]. Although dopamine receptors are abundantly
located in the proximal convoluted tubule, dopamine can
also induce natriuresis acting on distal nephron segments
[126]. The classical signaling pathway for D1-like receptors
leads to activation of AC and increases cAMP levels and PKA
activation. PKA may either directly phosphorylate a target
protein, such as a sodium transporting protein, or initiate a
cascade of phosphorylation events by phosphorylation and
activation of dopamine and cAMP-regulated phosphoprotein
DARPP32 [127]. D1R can also stimulate phospholipase C𝛽1
in renal tubules [128]. On the other hand, D2R can suppress
Akt (protein kinase B) signaling pathway [129]. Both types
of dopamine receptors are also linked to MAPK activation
through different pathways and can interact with each other,
resulting in new signaling pathways. In renal cortical cells
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the interaction between D1R and D2R increases PLC stim-
ulation [130].
Dopamine regulates ROS production in a biphasic man-
ner: at physiological concentrations, dopamine decreases
ROS production, via D1-like receptors, but at high con-
centrations (≥10 𝜇M) it stimulates ROS production [131–
133]. Although all dopamine receptor subtypes are capable
of decreasing ROS production, only the deletion of D2R
or D5R in mice has been associated with increased ROS
production [134]. NADPH oxidase activity can be inhibited
either by stimulation of D1R, via a PKA and PKC crosstalk,
or by direct stimulation of D5R or by indirect inhibition of
PLD [134–136]. D5R appears to be more implicated in ROS
regulation by dopamine. An experimental study carried out
in mice with D5R knockout demonstrated a higher level of
plasma thiobarbituric acid-reactive substances (TBARS) with
high expression and activity of NADPH oxidase [135, 136].
Besides, the D5R may also positively regulate antioxidants as
heme oxygenase 1 (HO-1) [137]. All these evidences suggest a
major role of D5R for preventing excessive ROS production.
Through D1R and D5R, dopamine stimulates antioxidant
enzymes like superoxide dismutase (SOD), glutathione per-
oxidase, glutamyl cysteine transferase, and HO-1 [138–140],
resulting in a diminished ROS production and antioxi-
dant protection. The D2R also exhibits antioxidant activity.
Endogenous antioxidants are necessary to counterbalance the
adverse effects of oxygen free radicals. In this way, Parkinson
protein 7 (PARK7 or DJ-1) is a peroxiredoxin-like peroxidase
that scavenges H
2
O
2
through oxidation of Cys-106 and
regulates the expression of several antioxidant genes, such as
SOD [140–145]. Another antioxidant factor is paraoxonase 2
(PON2), a cell-associated lipolactonase, located in lipid rafts
of brush border of proximal tubule that physically interacts
with D2R to counterregulate renal NADPH oxidase activity
and ROS production [146–148]. Heme oxygenase 2 (HO-2) is
another enzyme that degrades heme to generate biliverdin,
a metabolite with antioxidant properties [149, 150]. Like
D1-like receptors, the stimulation of D2R in the kidney is
associated with a decrease of oxidative stress by inhibition
of NADPH oxidase expression and increased expression of
the endogenous antioxidants DJ-1, PON2, and HO-2, all of
which can inhibit NADPH oxidase activity [148, 151]. On the
contrary, oxidative stress can affect negatively the function
of dopamine receptors.The G-protein receptor kinase (GRK,
a serine/threonine kinase) regulates renal D1R and D3R
by preventing their reassociation with G proteins, thereby
inducing its desensitization [152]. A decrease of intracellular
antioxidant factors in proximal tubular cells induces NF-
𝜅𝛽 translocation from the cytoplasm to the nucleus and,
subsequently, the upregulation of PKC activity and translo-
cation of GRK to the plasma membrane. In turn, GRK may
induce a serine hyperphosphorylation of D1R that leads to
uncoupling this receptor from the G-protein, thus impairing
its activity (Figure 4) [153–156]. In another study, Gross et al.
showed in a model of type 2 diabetes that a dopamine D3R
antagonist had a beneficial effect on renal morphology and
albuminuria, which was comparable in magnitude with that
of ACE-inhibitors treatment. In this model, glomerular and
tubulointerstitial expression of TGF-𝛽1, a marker of renal
fibrosis, was higher in diabetic rats and normalized by the
administration of the specificD3R antagonist A-437203 [157].
On the other hand, the increase of TGF-𝛽1 expression and its
targets Smad3 signaling and Snail1 in human renal proximal
tubule cells with D2R single-nucleotide polymorphisms has
been reported [158]. Although D1R and D2R are capable
of decreasing ROS production, there is still no evidence to
consider whether the antifibrotic effect of dopamine could be
mediated through suppression of ROS. Future studies should
be conducted to clarify this mechanism.
Altogether this evidence permits us to understand the
complexity of renal dopaminergic system and opens the
possibility of considering dopamine as a potential nephropro-
tective agent for future therapeutic strategies.
5. Renal Interaction between Vasoactive
Peptides and the Dopaminergic System
The observation that dopamine and ANP share similar
physiological effects suggests that each one may contribute
to enhancing the actions of the other. For the past decade,
several experimental studies have reported the possibility that
natriuretic peptide hormones and the renal dopaminergic
system could display a positive interaction. However, beside
these interesting observations, the intrinsic mechanisms
involved in ANP-dopamine relationship remain unclear and
continue to be under investigation. It has been reported that
part of the ANP inhibitory effects on sodium and water reab-
sorption depends on dopaminergicmechanisms, particularly
on dopamine receptors [159–164]. ANP can also potentiate
the inhibitory effect of dopamine on theNa+/H+ exchanger in
the proximal tubules and can recruit intracellular locatedD1R
to the plasma membrane, showing how ANP facilitates renal
dopamine effects [165, 166]. Another study that complements
and reinforces this ideawas reported byCorrea et al., showing
that ANP stimulates dopamine uptake by the tubular cells in
the kidney, via the stimulation of NPRA receptors, followed
by cGMP (as second messenger) and PKG activation. These
findings altogether show that ANP favors dopamine intracel-
lular accumulation, which in turn permits D1R recruitment
and stimulation, resulting in the overinhibition of Na+,
K+-ATPase activity, the decrease of sodium reabsorption,
and the increase of natriuresis [167, 168]. The interaction
between circulating ANP and locally formed dopamine in
the kidney must be taken into account, since both hor-
mones not only contribute to maintaining a well-balanced
regulation of sodium metabolism and blood pressure, but
also can potentiate their antioxidant and nephroprotective
properties.
There is evidence that dopamine exerts short- and long-
term natriuretic effects that oppose Ang II antinatriuretic
effects [169, 170]. This interaction between renal dopamine
and Ang II takes place mainly at receptor level and this inter-
action seems to be receptor subtype specific [118]. Dopamine
displays sustained effects via D1-like receptors, reducing
renal Ang II tonus, decreasing AT1R mRNA and protein
expression, and inducing AT2R-dependent natriuresis in
the kidney [170]. The first study concerning Ang II effects
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Figure 4: Renal dopamine receptors and its antioxidants properties. Dopamine (DA) binds to D1 receptor (D1R) coupled to stimulatory G
proteins (Gs and G𝛼) (1a) and to active adenylyl cyclase (AC) (1b) which in turn increases secondmessenger levels of cAMP (1c) and activates
the protein kinase A (PKA) (1d). PKA inhibits directly the Na/K exchanger (1e) in the apical membrane and also stimulates phospholipase
A
2
(PLA
2
) (1f). A metabolite of arachidonic acid (AA) (1g), 20-hydroxyeicosatetraenoic acid (20-HETE) (not shown) activates PKC (1h). In
addition, D1R via G protein (Gq) activates PLC (2a) with generation of inositol 1,3,4-trisphosphate (IP
3
) and diacylglycerol (DAG) (2b). IP
3
induces calcium (Ca++) release (2c) and DAG stimulates PKC (2d). Both PKA (1i) and PKC (2e) can inhibit Na+, K+-ATPase activity (1i) and
promote tubular sodium excretion. A crosstalk between PKA (1j) and PKC (2f) results in a negative regulation of NADPH oxidase (Nox)
activity. D2 receptors (D2R) are coupled to inhibitory G-protein (Gi/o) (3a) which inhibits AC activity.The D2-R stimulates the expression of
antioxidant complex (3b) such as Parkinson protein 7 (PARK-7), paraoxonase 2 (PON2), heme oxygenase 2 (HO-2), catalase, superoxide
dismutase (SOD), and glutathione peroxidase (3c). By displaying this antioxidant role, the physiological effect of D2R is to reduce Nox
(3d) activity. The activation of Nox (4a) leads to an imbalance in the redox state by generation of reactive oxygen species (ROS) (4b). This
conduces to an activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-𝜅B) in the cytoplasm and its translocation to
the nucleus (4c). NF-𝜅B promotes the transcription of several genes, including PKC (4d) and AT-1 receptor (4g). Activation of PKC stimulates
the translocation of G protein-coupled receptor kinase 2 (GRK-2) to themembrane (4e).TheGRK-2 causes D1R serine hyperphosphorylation
and uncoupling of G-protein to D1 receptor (4f). TEMPOL (5), an antioxidant permeable compound, reduces ROS production and prevents
cell damage by oxidative stress. Thin red arrows indicate inhibition. Thick green arrows indicate activation.
on renal dopamine uptake concluded that Ang II inhibits
dopamine uptake in renal tissues through stimulation of
AT1R and signals through the PLC pathway, including the
generation of second messengers, IP
3
and DAG, intracellular
calcium release, and activation of PKC and CaM kinase II.
These effects altogethermay prevent dopamine accumulation
into renal tubular cells, resulting in a decrease of dopamine
availability inside the cell and at the luminal side of the
nephron. These mechanisms may prevent homologous D1R
recruitment and stimulation, which in turn would result
in disinhibition of Na+, K+-ATPase activity and the con-
sequently increase of sodium reabsorption and decrease of
natriuresis [171–173]. On the other hand, AT2R and D1R
oppose each other cooperatively to counteract the vasocon-
strictor and antinatriuretic functions elicited by AT1R. It has
been demonstrated that in vivo administration of fenoldopam
(a highly selective D1-like receptor agonist) in sodium loaded
Sprague Dawley rats induces the translocation of AT2R from
intracellular compartment to the apical plasma membranes
[174]. The fact that fenoldopam-induced natriuretic response
was completely inhibited by the intrarenal coinfusion of the
AT2R antagonist, PD 123390, reinforces this concept [175].
The D3R displays inhibitory effect on renin secretion, while
D4R and D5R decrease AT1R expression [176]. D1R as well as
D3R inhibit Ang II effects by their heterodimerization with
the AT1R [177–179]. In renal proximal tubule cells, D5R can
also decrease AT1R expression and its signaling transduction
by a c-Src-dependent and proteasome-dependent process
[180–182]. ROS can also inactivate D1R and activate AT1R
[183]. It has been recently reported that oxidative stress plays a
central role in the development of hypertension in old Fischer
344 × Brown Norway F1 rats [184]. In this experimental
model, NF-𝜅B diminished renal D1R function and promoted
the transcription of AT1R gene, which resulted in high blood
pressure levels with aging [184]. Other authors showed that
reduction in intrarenal dopamine synthesis is associated
with increased detrimental effects of Ang II on renal injury
[185, 186]. All these evidences about the interaction between
angiotensin and dopamine receptors must be taken into
consideration, since both hormones exhibit opposite effects
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not only on sodium balance and blood pressure, but also on
oxidative stress.
6. Conclusion and Future Perspectives
Although there is evidence that a defective renal dopaminer-
gic system contributes to the development and maintenance
of hypertension, it is still not clear what triggering factor
causes the selective defect in the renal dopaminergic system.
Some of these trigger factors could be an excess of sodium
intake that could lead to an activation of intrarenal Ang II
and increase in ROS, an increase in carbohydrate intake and
a high fat diet, both factors that promote insulin resistance.
Furthermore, the renal dopaminergic system is sensitized
by a high salt intake and volume expansion, which opens
the question about how intrarenal sodium sensors may
influence renal dopamine bioavailability. The observation
that dopamine receptors availability in the plasmamembrane
may be regulated by other hormones, likeANP, could open up
a possible therapeutic approach.
A physiological balance between oxidant and antioxidant
systems is necessary to maintain the redox equilibrium in a
steady state. In the kidney, an increase in oxidative stress is
frequently associated with the development of hypertension
and renal inflammation.
Therefore, the comprehension of the signaling network
triggered by different hormones like ANP, Ang II, and renal
dopamine that regulates the production and catabolism of
endogenous prooxidant and antioxidant enzymes and mod-
ulates the signaling pathways closely related to the oxidative
stress will provide a new insight about the pathophysiology of
renal inflammation and injury and contribute to improving
diagnosis tools, evolution, prognosis, and treatment of renal
pathologies.
This could open a new possibility for therapeutic strate-
gies beyond the blockade of RAAS. In this sense, future
pharmacological agents targeting maintaining optimal levels
of ANP and/or intrarenal dopamine can be proposed as novel
nephroprotective agents to prevent renal damage by oxidative
stress.
The administration of synthesized analogous of natri-
uretic peptides (as nesiritide and anaritide) or inhibitors
of the catabolic enzyme 24.11 endopeptidase (candoxatril,
omapatrilat, neprilysin, and ecadotril) may be a useful tool
to regulate the expression of key components of tubulointer-
stitial inflammation in the kidney and to control the oxygen
supply or demand, under circumstances of sodium overload.
In a similar sense, the use of antioxidants and Ang II-AT1R
blockers (losartan and candesartan) to inhibit the RAASmay
contribute to improving the treatment of oxidative stress-
derived renal pathologies.
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